SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Glaxosmithkline PLC, et al. – ‘CORRESP’ from 4/13/17

On:  Thursday, 4/13/17, at 2:03pm ET   ·   Private-to-Public:  Filing  –  Release Delayed to:  5/19/17   ·   Accession #:  903423-17-270

Previous ‘CORRESP’:  ‘CORRESP’ on 8/3/16   ·   Next & Latest:  ‘CORRESP’ on 8/31/21

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/13/17  Glaxosmithkline PLC               CORRESP5/19/17    1:18K                                    Cleary Gottlieb Ste… LLP
          Glaxosmithkline Capital Inc
          Glaxosmithkline Capital PLC

Delayed-Release Comment-Response or Other Letter to the SEC
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: CORRESP     Comment-Response or Other Letter to the SEC         HTML     10K 


This is an HTML Document rendered as filed.  [ Alternative Formats ]



 

 

                          April 13, 2017

 

 

VIA EDGAR

 

Ms. Christine Westbrook

Division of Corporation Finance

Securities and Exchange Commission
100 F Street, NE

Washington, DC 20549

Re:

GlaxoSmithKline plc

GlaxoSmithKline Capital Inc.

GlaxoSmithKline Capital plc

Registration Statement on Form F-3 (File No. 333-217125)

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, GlaxoSmithKline plc, GlaxoSmithKline Capital Inc. and GlaxoSmithKline Capital plc (together, the “Registrants”) hereby request that the effectiveness of the above-captioned Registration Statement be accelerated to 9:00 a.m. (Eastern Daylight Time) on Tuesday, April 18, 2017, or as soon thereafter as practicable.

 

In connection with this request, the Registrants acknowledge to the U.S. Securities and Exchange Commission (the “Commission”) that:

·should the Commission or the staff of the Commission (the “Staff”), acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
·the action of the Commission or the Staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrants from their full responsibility for the adequacy and accuracy of the disclosure in the filing; and
·the Registrants may not assert the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

*       *       *

 C: 
 
 

 

Very truly yours,

GLAXOSMITHKLINE PLC

 

 

By: /s/ Simon Dingemans                        

 

Name:     Simon Dingemans

Title:        Chief Financial Officer and Executive Director

 

 

GLAXOSMITHKLINE CAPITAL INC.

 

 

By: /s/ Simon Dingemans                        

 

Name:     Simon Dingemans

Title:       President

 

 

GLAXOSMITHKLINE CAPITAL PLC

 

 

By: /s/ Simon Dingemans                        

 

Name:     Simon Dingemans

Title:       Director

 

 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘CORRESP’ Filing    Date    Other Filings
Release Delayed to:5/19/17UPLOAD
4/18/176-K,  EFFECT
Filed on:4/13/17SC 13D/A,  UPLOAD
 List all Filings 
Top
Filing Submission 0000903423-17-000270   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., May 13, 9:30:43.1pm ET